Nkarta Inc (NKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nkarta Inc (NKTX) has a cash flow conversion efficiency ratio of -0.099x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.20 Million) by net assets ($285.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nkarta Inc (NKTX) defensive interval to measure how many days the company can operate on defensive assets alone.
Nkarta Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nkarta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nkarta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nkarta Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eaton Vance New York MBF
NYSE MKT:ENX
|
0.037x |
|
Lanson BCC SA
PA:ALLAN
|
0.016x |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
4.017x |
|
Green Cross Lab Cell Corporation
KQ:144510
|
0.015x |
|
Binh Dinh Pharmaceutical and Medical Equipment JSC
VN:DBD
|
-0.075x |
|
Nordic Aqua Partners As
OL:NOAP
|
-0.140x |
|
Associated Alcohols & Breweries Ltd.
NSE:ASALCBR
|
0.080x |
|
Dynamix Corp
NASDAQ:DYNC
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Nkarta Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nkarta Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Nkarta Inc (NKTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $312.32 Million | $-88.70 Million | -0.284x | -16.22% |
| 2024-12-31 | $407.98 Million | $-99.70 Million | -0.244x | +22.49% |
| 2023-12-31 | $273.29 Million | $-86.16 Million | -0.315x | -105.87% |
| 2022-12-31 | $372.21 Million | $-57.00 Million | -0.153x | +43.42% |
| 2021-12-31 | $250.97 Million | $-67.93 Million | -0.271x | -99.84% |
| 2020-12-31 | $321.22 Million | $-43.51 Million | -0.135x | -118.79% |
| 2019-12-31 | $-25.48 Million | $-18.37 Million | 0.721x | -24.97% |
| 2018-12-31 | $-5.40 Million | $-5.18 Million | 0.961x | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more